IL217792D0 - Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic - Google Patents

Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Info

Publication number
IL217792D0
IL217792D0 IL217792A IL21779212A IL217792D0 IL 217792 D0 IL217792 D0 IL 217792D0 IL 217792 A IL217792 A IL 217792A IL 21779212 A IL21779212 A IL 21779212A IL 217792 D0 IL217792 D0 IL 217792D0
Authority
IL
Israel
Prior art keywords
dosage forms
pharmaceutical dosage
opioid analgesic
tamper resistant
oral pharmaceutical
Prior art date
Application number
IL217792A
Other versions
IL217792A (en
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US84024406P priority Critical
Priority to PCT/IB2007/002515 priority patent/WO2008023261A1/en
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of IL217792D0 publication Critical patent/IL217792D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL217792(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of IL217792A publication Critical patent/IL217792A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005Coating of tablets or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00Mixing; Kneading
    • B29B7/02Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00Mixing; Kneading
    • B29B7/80Component parts, details or accessories; Auxiliary operations
    • B29B7/88Adding charges, i.e. additives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16Cooling
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C37/00Component parts, details, accessories or auxiliary operations, not covered by group B29C33/00 or B29C35/00
    • B29C37/0025Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/32Component parts, details or accessories; Auxiliary operations
    • B29C43/52Heating or cooling
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00After-treatment of articles without altering their shape; Apparatus therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00After-treatment of articles without altering their shape; Apparatus therefor
    • B29C71/009After-treatment of articles without altering their shape; Apparatus therefor using gases without chemical reaction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B29C2035/046Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames dried air
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16Cooling
    • B29C2035/1658Cooling using gas
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035Medical or pharmaceutical agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25Solid
    • B29K2105/251Particles, powder or granules
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037Other properties
    • B29K2995/0088Molecular weight
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29LINDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00Other particular articles
    • B29L2031/753Medical equipment; Accessories therefor

Abstract

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
IL217792A 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic IL217792A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US84024406P true 2006-08-25 2006-08-25
PCT/IB2007/002515 WO2008023261A1 (en) 2006-08-25 2007-08-24 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Publications (2)

Publication Number Publication Date
IL217792D0 true IL217792D0 (en) 2012-03-29
IL217792A IL217792A (en) 2015-09-24

Family

ID=38754532

Family Applications (10)

Application Number Title Priority Date Filing Date
IL197214A IL197214A (en) 2006-08-25 2009-02-24 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217792A IL217792A (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217790A IL217790D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217794A IL217794A (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217788A IL217788D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217789A IL217789D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217787A IL217787D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217791A IL217791A (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL241122A IL241122A (en) 2006-08-25 2015-09-03 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL241121A IL241121A (en) 2006-08-25 2015-09-03 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL197214A IL197214A (en) 2006-08-25 2009-02-24 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Family Applications After (8)

Application Number Title Priority Date Filing Date
IL217790A IL217790D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217794A IL217794A (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217788A IL217788D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217789A IL217789D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217787A IL217787D0 (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL217791A IL217791A (en) 2006-08-25 2012-01-26 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL241122A IL241122A (en) 2006-08-25 2015-09-03 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
IL241121A IL241121A (en) 2006-08-25 2015-09-03 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Country Status (42)

Country Link
US (55) US8894987B2 (en)
EP (11) EP2384754B1 (en)
JP (8) JP5069300B2 (en)
KR (7) KR20170118249A (en)
CN (9) CN105213345B (en)
AP (1) AP2355A (en)
AR (4) AR062511A1 (en)
AT (5) AT499101T (en)
AU (1) AU2007287341B2 (en)
BR (1) BRPI0714539A2 (en)
CA (2) CA2661573C (en)
CL (3) CL2007002485A1 (en)
CO (1) CO6160317A2 (en)
CR (2) CR10691A (en)
CY (7) CY1110573T1 (en)
DE (5) DE602007010974D1 (en)
DK (11) DK2080514T3 (en)
DO (2) DOP2009000026A (en)
EA (3) EA023807B1 (en)
ES (11) ES2388591T3 (en)
GT (2) GT200900023A (en)
HK (11) HK1118225A1 (en)
HR (11) HRP20090688T1 (en)
IL (10) IL197214A (en)
IN (1) IN2015DN01813A (en)
JO (2) JO2858B1 (en)
MA (1) MA30766B1 (en)
ME (7) ME01550B (en)
MX (2) MX2009002023A (en)
MY (3) MY146650A (en)
NZ (3) NZ574447A (en)
PE (4) PE20140854A1 (en)
PL (9) PL2311459T3 (en)
PT (11) PT2080514E (en)
RS (11) RS52779B (en)
SA (1) SA2709B1 (en)
SI (11) SI2311459T1 (en)
TN (1) TN2009000059A1 (en)
TW (1) TWI341213B (en)
UA (2) UA96306C2 (en)
WO (1) WO2008023261A1 (en)
ZA (1) ZA200900755B (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ES2350689T3 (en) 2002-12-13 2011-01-26 Durect Corporation Oral drug supply system that includes high viscosity liquid vehicle materials.
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (en) * 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102004032103A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
BRPI0515372A (en) 2004-09-17 2008-07-22 Durect Corp composition, and method for providing an anesthetic effect to a site in an individual
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102005005449A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
CN101188999B (en) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 A pharmaceutical delivery system for delivering active component dispersed in dispersion medium
SA2709B1 (en) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
DE102007011485A1 (en) * 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
CA2696341C (en) * 2007-08-13 2016-05-17 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
TWI454288B (en) * 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
JP5607550B2 (en) * 2008-03-11 2014-10-15 ディポメド,インコーポレイティド Gastric retentive sustained release dosage form comprising a combination of a non-opioid analgesic and an opioid analgesic
ES2599031T3 (en) 2008-05-09 2017-01-31 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spray freezing step
NZ601200A (en) * 2008-09-18 2014-02-28 Purdue Pharma Lp Pharmaceutical dosage forms comprising poly(epsilon-caprolactone)
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
MX2011006173A (en) 2008-12-12 2011-09-01 Paladin Labs Inc Narcotic drug formulations with decreased abuse potential.
ES2607209T3 (en) 2009-02-06 2017-03-29 Egalet Ltd. Abuse resistant pharmaceutical compositions
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010127108A2 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
US20100278915A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
WO2011009603A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive oploids
CN102596252A (en) * 2009-08-31 2012-07-18 蒂宝制药公司 Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
BR112012028656A2 (en) 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CN102946870A (en) 2010-05-10 2013-02-27 欧洲凯尔特公司 Pharmaceutical compositions comprising hydromorphone and naloxone
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
US9233076B2 (en) 2010-12-13 2016-01-12 Purdue Pharma L.P. Controlled release dosage forms
EP2654734A2 (en) 2010-12-22 2013-10-30 Purdue Pharma LP Encased tamper resistant controlled release dosage forms
CN104856966A (en) * 2010-12-22 2015-08-26 普渡制药公司 Encased tamper resistant controlled release dosage forms
NZ612996A (en) 2010-12-23 2015-05-29 Purdue Pharma Lp Tamper resistant solid oral dosage forms
SI2688556T1 (en) * 2011-03-25 2015-09-30 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
AT511581A1 (en) 2011-05-26 2012-12-15 G L Pharma Gmbh Oral retardant formulation
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP6110384B2 (en) * 2011-09-16 2017-04-05 パーデュー ファーマ エルピー Tamper-resistant pharmaceutical formulation
JP6138798B2 (en) * 2011-09-16 2017-05-31 パーデュー ファーマ エルピー Tamper-resistant immediate release formulation
CN103889456A (en) * 2011-10-18 2014-06-25 普渡制药公司 Acrylic polymer formulations
WO2013072395A1 (en) 2011-11-17 2013-05-23 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
US20150224097A1 (en) * 2011-11-22 2015-08-13 Watson Pharmaceuticals, Inc. Immediate Release Abuse Deterrent Tablet
EP2787978B1 (en) * 2011-12-09 2016-09-21 Purdue Pharma LP Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
JP6117249B2 (en) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer
CA2864738C (en) 2012-04-18 2017-07-18 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
RS57913B1 (en) 2012-04-18 2019-01-31 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015000150A2 (en) 2012-07-06 2017-06-27 Egalet Ltd controlled release abuse deterrent pharmaceutical compositions
PL2872121T3 (en) 2012-07-12 2019-02-28 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
CN108743549A (en) 2012-11-30 2018-11-06 阿库拉制药公司 The self-regulation of active pharmaceutical ingredient discharges
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
PL2968182T3 (en) 2013-03-15 2018-10-31 SpecGx, LLC Abuse deterrent solid dosage form for immediate release with functional score
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US20160131011A1 (en) * 2013-05-27 2016-05-12 Volvo Truck Corporation Method for timing a regeneration process
MX2015016112A (en) 2013-05-29 2016-03-31 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles.
BR112015029616A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-resistant dosage form with bimodal release profile
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
MX2016014738A (en) 2014-05-12 2017-03-06 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol.
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2955229A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
JP5888387B1 (en) * 2014-10-22 2016-03-22 ミツミ電機株式会社 Battery protection circuit, battery protection device, and battery pack
US20160310486A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
JP2018515455A (en) 2015-04-24 2018-06-14 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant fixed dose combination resulting in rapid release of two drugs from particles
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2983640A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
WO2017059374A1 (en) * 2015-09-30 2017-04-06 Kashiv Pharma Llc Overdose protection and abuse deterrent immediate release drug formulation
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US20180303757A1 (en) 2015-10-23 2018-10-25 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
JP6323846B2 (en) * 2016-04-07 2018-05-16 塩野義製薬株式会社 Abuse prevention formulation containing opioid
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018024709A1 (en) 2016-08-01 2018-02-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polysaccharide
BR112019002789A2 (en) 2016-08-12 2019-05-21 Gruenenthal Gmbh ephedrine formulation tamper resistant and derivatives
DE202016105585U1 (en) * 2016-10-06 2017-01-23 L.B. Bohle Maschinen + Verfahren Gmbh Plant for the production of pharmaceutical tablets
USD857156S1 (en) * 2016-11-02 2019-08-20 Innovative Water Care, Llc Chemical tablet for aquatic systems
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019003062A1 (en) * 2017-06-29 2019-01-03 Zenvision Pharma Llp Tamper-proof dosage form comprising pharmaceutically active agent
US20190110992A1 (en) 2017-10-13 2019-04-18 Grünenthal GmbH Modified release abuse deterrent dosage forms
WO2019126125A1 (en) * 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
US20190247332A1 (en) 2018-02-09 2019-08-15 Grünenthal GmbH Tamper resistant formulation of ephedrine and its derivatives comprising a conversion inhibitor

Family Cites Families (284)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1468805A (en) 1923-09-25 Htabtin ereund
US1479293A (en) 1924-01-01 Hiabtor fbettlid
US1485673A (en) * 1924-03-04 Ministrator
US636438A (en) 1899-02-08 1899-11-07 Charles H Lovejoy Molder's chaplet.
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3097144A (en) 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US3806603A (en) * 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3885027A (en) 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966747A (en) * 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US3941865A (en) * 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
DE2530563C2 (en) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen, De
GB1598458A (en) 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4501828A (en) * 1983-01-20 1985-02-26 General Technology Applications,Inc. Dissolving water soluble polymers
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
FR2557459B1 (en) 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique inert matrix based on polycaprolactone for oral administration of a drug, and method of preparing the dosage form comprising said matrix
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
AU592065B2 (en) 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4616644A (en) 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
US4774092A (en) 1985-06-24 1988-09-27 Ici Australia Limited Ingestible capsules
US4619988A (en) 1985-06-26 1986-10-28 Allied Corporation High strength and high tensile modulus fibers or poly(ethylene oxide)
EP0227806B1 (en) 1985-06-28 1989-08-30 Carrington Laboratories, Inc. Processes for preparation of aloe products, products produced thereby and compositions thereof
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
DE3689650T2 (en) 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbable polymers of high molecular weight and implants it.
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
WO1988003408A1 (en) 1986-11-10 1988-05-19 Biopure Corporation Extra pure semi-synthetic blood substitute
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) * 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5051222A (en) 1989-09-01 1991-09-24 Air Products And Chemicals, Inc. Method for making extrudable polyvinyl alcohol compositions
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
FR2664851B1 (en) * 1990-07-20 1992-10-16 Oreal Method for compacting a powder mixture to obtain an absorbent or partially friable compact product and product obtained by this process.
SE9003904D0 (en) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
WO1993006723A1 (en) 1991-10-04 1993-04-15 Olin Corporation Fungicide tablet
EP0612253A4 (en) * 1991-11-12 1995-08-09 Nepera Inc Adhesive hydrogels having extended use lives and process for the preparation of same.
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
EP0615438B1 (en) 1991-12-05 1996-07-24 Mallinckrodt Veterinary, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
CA2124821C (en) 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
JP2640570B2 (en) 1992-01-13 1997-08-13 ファイザー インク. Manufacture of tablets strength is increased
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5393528A (en) * 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
DE4227385A1 (en) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh pancreatin
JP3140465B2 (en) * 1992-09-18 2001-03-05 山之内製薬株式会社 Hydrogel sustained-release preparation
FI101039B (en) 1992-10-09 1998-04-15 Eeva Kristoffersson Process for the preparation of drug pellets
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
FR2701152B1 (en) 1993-02-03 1995-03-10 Digipress Sa A method of manufacturing a master disk for producing a stamper including optical discs, stamper obtained by this method and optical disk obtained from this stamper.
DE4309528C2 (en) 1993-03-24 1998-05-20 Doxa Gmbh Film or film tubing from casein, process for their preparation and their use
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US5849240A (en) 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
DE69429710T2 (en) 1993-11-23 2002-08-08 Euro Celtique Sa A process for preparing a pharmaceutical composition having sustained-release
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
DE69530973D1 (en) 1994-02-16 2003-07-10 Abbott Lab A process for preparing finely divided pharmaceutical formulations
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DK0758244T4 (en) 1994-05-06 2008-06-16 Pfizer Controlled-release azithromycin dosage forms
AT403988B (en) 1994-05-18 1998-07-27 Lannacher Heilmittel Solid oral sustained-release
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
DE4426245A1 (en) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds having pharmacological activity
CA2130410C (en) 1994-08-18 2001-12-04 Albert John Kerklaan Retractable expandable jack
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (en) * 1994-12-23 1996-06-27 Basf Ag A process for the production of divisible tablets
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
AT214596T (en) 1995-04-14 2002-04-15 Pharma Pass Solid compositions with a non-amorphous active ingredient and polyethylene oxide
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19547766A1 (en) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
ES2168610T3 (en) * 1996-03-12 2002-06-16 Alza Corp Composition and dosage form containing an opioid antagonist.
US20020114838A1 (en) * 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
US6136864A (en) 1996-04-10 2000-10-24 Warner-Lambert Company Denaturants for sympathomimetic amine salts
US5886164A (en) * 1996-04-15 1999-03-23 Zeneca Limited DNA encoding enzymes related to ethylene biosynthesis and ripening from banana
EP0974343B1 (en) 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
AT427124T (en) 1996-06-26 2009-04-15 Univ Texas Hot-molly extrudable pharmaceutical formulation
DE19630236A1 (en) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxially stretched, biodegradable and compostable sausage casing
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
BE1010353A5 (en) 1996-08-14 1998-06-02 Boss Pharmaceuticals Ag Method for manufacture of pharmaceutical products, device for such a method and pharmaceutical products obtained.
AT278737T (en) 1996-11-05 2004-10-15 Novamont Spa contain Biologiscgh abbaure polymer compositions, the starch and a thermoplastic polymer
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
FR2761605B1 (en) 1997-04-07 2001-02-23 Prographarm Lab multiparticulate pharmaceutical form, its constituent particles, and METHOD plant to produce
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
IL121038D0 (en) 1997-06-09 1997-11-20 Technion Res & Dev Foundation A pharmaceutical composition for lowering glucose level in blood
DE19724181A1 (en) 1997-06-09 1998-12-10 Bayer Ag Multiple-unit-retard preparations and methods for their preparation
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
BR9812828A (en) * 1997-09-26 2000-08-08 Magna Interior Sys Inc Fastener assembly for attaching and aligning two panels, and method for installing a supported panel to a supporting panel
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19758564A1 (en) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulation of a combination of morphine and a alpha¶2¶-adrenergic agonists and their use
ES2174538T3 (en) * 1997-11-28 2002-11-01 Knoll Ag Procedure for obtaining substances exempt solvent, noncrystalline, biologically active.
DE19753534A1 (en) 1997-12-03 1999-06-10 Bayer Ag Biodegradable thermoplastic polyester-amides with good mechanical properties for molding, film and fiber, useful for e.g. compostable refuse bag
GB9726365D0 (en) 1997-12-13 1998-02-11 Ciba Sc Holding Ag Compounds
PT1041987E (en) 1997-12-22 2006-07-31 Euro Celtique Sa Pharmaceutical form of oral dosage, understanding a combination of an agronist of opioide and naltrexone
KR100417490B1 (en) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 A method of preventing abuse of opioid dosage forms
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19800698A1 (en) 1998-01-10 1999-07-15 Bayer Ag Biodegradable polyester with block-type structure polyester and polyamide segments
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
WO1999045067A1 (en) 1998-03-05 1999-09-10 Mitsui Chemicals, Inc. Polylactic acid composition and film thereof
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
DE19822979A1 (en) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Film with starch or starch derivatives and polyester urethanes, as well as processes for their preparation
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
DE19855440A1 (en) 1998-12-01 2000-06-08 Basf Ag A method for producing solid dosage forms by melt extrusion
IE981008A1 (en) 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
DE19901683B4 (en) 1999-01-18 2005-07-21 Grünenthal GmbH Controlled-release analgesic
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
ES2226886T3 (en) 1999-08-31 2005-04-01 Grunenthal Gmbh Form of administration of delayed action containing squarinate of tramadol.
DE19940944B4 (en) * 1999-08-31 2006-10-12 Grünenthal GmbH Retarded, oral, pharmaceutical dosage forms
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
DE19960494A1 (en) * 1999-12-15 2001-06-21 Knoll Ag Device and method for producing solid active substance-containing forms
AU2292901A (en) 1999-12-23 2001-07-03 Combe International Ltd. Dental adhesive device and method for producing same
ECSP003314A (en) 2000-01-11 2000-03-22 pharmaceutical formulations containing delayed a combination of an opioid and - agonist
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10015479A1 (en) 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
DE10025948A1 (en) 2000-05-26 2001-11-29 Gruenenthal Gmbh drug combination
DE10025947A1 (en) 2000-05-26 2001-11-29 Gruenenthal Gmbh Active compound combination comprising Montirelin and a compound having opioid activity
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10036400A1 (en) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh White, biaxially oriented polyester film
AU9490201A (en) 2000-09-28 2002-04-08 Dow Chemical Co Polymer composite structures useful for controlled release systems
KR101167465B1 (en) * 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
KR20060028821A (en) 2001-05-02 2006-04-03 유로-셀티크 소시에떼 아노뉨 Once-a-day oxycodone formulations
CN1592609A (en) * 2001-05-11 2005-03-09 恩德制药公司 Abuse-resistant opioid dosage form
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
AT376832T (en) * 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co Delayed forculating formulations of oxymorphone
HU0401195A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Compositions to prevent abuse of opioids containing aversive agent and process of their preparation
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
WO2003015531A2 (en) 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
KR20040025741A (en) 2001-08-06 2004-03-25 유로-셀티크 소시에떼 아노뉨 Compositions and methods to prevent abuse of opioids
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030069318A1 (en) * 2001-08-21 2003-04-10 Wenbin Dang Salts of analgesic substances in oil, and methods of making and using the same
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
AU2002342755A1 (en) 2001-09-26 2003-04-14 Klaus-Jurgen Steffens Method and device for producing granulates that comprise at least one pharmaceutical active substance
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
BR0314547A (en) * 2002-09-28 2005-08-09 Mcneil Ppc Inc Immediate release dosage form comprising a shell having openings therein
BR0213588A (en) 2001-09-28 2004-08-31 Mcneil Ppc Inc Modified release dosage
US20030229158A1 (en) 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
PE20030527A1 (en) 2001-10-24 2003-07-26 Gruenenthal Chemie Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt of the same and tablets for oral administration which contain
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
FR2833838B1 (en) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Method for manufacturing a tablet including a morphinic type analgesic and a compress obtained
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
WO2003072025A2 (en) 2002-02-21 2003-09-04 Biovail Laboratories Inc. Modified release formulations of at least one form of tramadol
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
DE10217232B4 (en) * 2002-04-18 2004-08-19 Ticona Gmbh A method for preparing filled granules of polyethylenes high or ultra-high molecular weight
DE60325715D1 (en) * 2002-04-29 2009-02-26 Alza Corp Methods and pharmaceutical for the controlled release of oxycodone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
CA2486075A1 (en) 2002-05-13 2003-11-20 Endo Pharmaceuticals Inc. Abuse-resistant opioid solid dosage form
EP1506174B1 (en) * 2002-05-17 2015-09-30 Taiwanj Pharmaceuticals Co., Ltd. Use of naltrexone for treating kidney and liver damage
PL372797A1 (en) 2002-05-31 2005-08-08 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250083A1 (en) 2002-06-17 2003-12-24 Gruenenthal Gmbh Abuse-proofed dosage form
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040011806A1 (en) * 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
AU2003261223A1 (en) 2002-07-25 2004-02-16 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
CN100439373C (en) 2002-08-15 2008-12-03 诺拉姆科有限公司 Oxycodone-hydrochloride polymorhs
MXPA05002891A (en) 2002-09-20 2005-06-22 Fmc Corp Cosmetic composition containing microcrystalline cellulose.
JP5189242B2 (en) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッドAlkermes Pharma Ireland Limited Abuse-resistant pharmaceutical composition
DE10250088A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE10250087A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
US7456617B2 (en) * 2002-11-13 2008-11-25 Power-One, Inc. System for controlling and monitoring an array of point-of-load regulators by a host
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
MXPA05011071A (en) 2003-04-21 2005-12-12 Euro Celtique Sa Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same.
CA2522529C (en) 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
EP1624859A4 (en) 2003-05-06 2010-06-23 Bpsi Holdings Inc Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same
US20040241234A1 (en) 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050031655A1 (en) 2003-08-04 2005-02-10 Schering Plough Healthcare Products, Inc. Emulsion composition
PL1658054T3 (en) * 2003-08-06 2007-11-30 Grã¼Nenthal Gmbh Dosage form that is safeguarded from abuse
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
CA2874604A1 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
WO2005041968A2 (en) 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE10361596A1 (en) * 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
WO2005070760A1 (en) 2004-01-23 2005-08-04 Antoine Sakellarides Shock absorbing system for rowing boat oarlock
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP2319499A1 (en) 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
TWI483944B (en) 2004-03-30 2015-05-11 Euro Celtique Sa Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone
EP1740156B8 (en) * 2004-04-22 2012-07-11 Grünenthal GmbH Method for the production of an abuse-proof, solid form of administration
DE102004020220A1 (en) 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
JP2006002886A (en) * 2004-06-18 2006-01-05 Noriatsu Kojima Drain pipe
JP2006002884A (en) * 2004-06-18 2006-01-05 Mitsubishi Plastics Ind Ltd Connector
CA2571010A1 (en) * 2004-06-22 2006-01-05 Magna International Inc. Sealing molding for a motor vehicle
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102004032051A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
AR049562A1 (en) 2004-07-01 2006-08-16 Gruenenthal Gmbh Oral dosage forms, controlled release opioid protected against abuse and process for their preparation
WO2006002883A1 (en) 2004-07-01 2006-01-12 Grünenthal GmbH Method for producing a solid dosage form, which is safeguarded against abuse, while using a planetary gear extruder
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20080274183A1 (en) 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
JP5371427B2 (en) 2005-07-07 2013-12-18 ファーナム・カンパニーズ・インコーポレーテッド Sustained release pharmaceutical composition for highly water-soluble drugs
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
SA2709B1 (en) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
WO2008089087A2 (en) 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
NZ577560A (en) 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
JP5607550B2 (en) 2008-03-11 2014-10-15 ディポメド,インコーポレイティド Gastric retentive sustained release dosage form comprising a combination of a non-opioid analgesic and an opioid analgesic
US10080721B2 (en) * 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9492492B2 (en) * 2010-12-17 2016-11-15 Johnson & Johnson Consumer Inc. Compositions comprising Lilium martagon extracts and uses thereof
US9846413B2 (en) * 2011-09-08 2017-12-19 Fire Avert, Llc. Safety shut-off device and method of use

Also Published As

Publication number Publication date
KR20140049085A (en) 2014-04-24
IL217794D0 (en) 2012-03-29
EA018311B1 (en) 2013-07-30
US20170128375A1 (en) 2017-05-11
DK2311459T3 (en) 2012-09-10
KR101787605B1 (en) 2017-10-19
CN101583360B (en) 2014-02-26
US9763886B2 (en) 2017-09-19
CN102743355A (en) 2012-10-24
RS52463B (en) 2013-02-28
US20170065527A1 (en) 2017-03-09
US9101661B2 (en) 2015-08-11
US8846086B2 (en) 2014-09-30
EP2399579B1 (en) 2013-04-03
PT2311459E (en) 2012-09-26
AT499101T (en) 2011-03-15
DK2399580T3 (en) 2013-06-24
ES2388615T3 (en) 2012-10-17
HK1165318A1 (en) 2013-12-06
US8808741B2 (en) 2014-08-19
US9492390B2 (en) 2016-11-15
US20180153814A1 (en) 2018-06-07
SI2311459T1 (en) 2012-10-30
US20140024669A1 (en) 2014-01-23
MY146650A (en) 2012-09-14
PE20140854A1 (en) 2014-07-19
PL2343071T3 (en) 2013-12-31
KR20090045381A (en) 2009-05-07
DE602007002596D1 (en) 2009-11-12
DE602007010974D1 (en) 2011-01-13
US20150037413A1 (en) 2015-02-05
IL197214A (en) 2015-09-24
CO6160317A2 (en) 2010-05-20
PL2080514T3 (en) 2011-09-30
EP1897545B1 (en) 2009-09-30
CA2707204A1 (en) 2008-02-28
US20190000767A1 (en) 2019-01-03
HRP20120670T1 (en) 2012-09-30
JP2010501543A (en) 2010-01-21
AT489954T (en) 2010-12-15
SI2082742T1 (en) 2011-03-31
US9770417B2 (en) 2017-09-26
US20130251799A1 (en) 2013-09-26
KR20120105566A (en) 2012-09-25
US20150028512A1 (en) 2015-01-29
EP1897545A1 (en) 2008-03-12
CR10691A (en) 2009-06-05
ES2361721T3 (en) 2011-06-21
DK2292230T3 (en) 2012-08-20
IL217792A (en) 2015-09-24
RS52793B (en) 2013-10-31
ME01064B (en) 2012-10-20
US20130259940A1 (en) 2013-10-03
US9775809B2 (en) 2017-10-03
US20180153815A1 (en) 2018-06-07
AP2355A (en) 2012-01-26
JP5980881B2 (en) 2016-08-31
RS51162B (en) 2010-10-31
KR20150082669A (en) 2015-07-15
AR103463A2 (en) 2017-05-10
US20150037412A1 (en) 2015-02-05
US20130259938A1 (en) 2013-10-03
EA201300465A1 (en) 2013-08-30
US8894988B2 (en) 2014-11-25
AT444070T (en) 2009-10-15
ZA200900755B (en) 2009-12-30
MA30766B1 (en) 2009-10-01
US20170128374A1 (en) 2017-05-11
US9084816B2 (en) 2015-07-21
CY1113231T1 (en) 2016-04-13
AR109796A2 (en) 2019-01-23
US20170354607A1 (en) 2017-12-14
US20150335580A1 (en) 2015-11-26
JO3323B1 (en) 2019-03-13
US20180369150A1 (en) 2018-12-27
HRP20090688T1 (en) 2010-02-28
EA031873B1 (en) 2019-03-29
MX360849B (en) 2018-11-20
US20130251797A1 (en) 2013-09-26
IL241121A (en) 2017-09-28
CL2014001029A1 (en) 2014-09-12
CN102657630A (en) 2012-09-12
HRP20110375T1 (en) 2011-06-30
PT2399579E (en) 2013-06-24
US9492389B2 (en) 2016-11-15
CR20140340A (en) 2014-10-16
EP2384754B1 (en) 2013-03-20
EP2070538B1 (en) 2010-12-01
EP2292229A1 (en) 2011-03-09
US20150265600A1 (en) 2015-09-24
IL217790D0 (en) 2012-03-29
HK1133192A1 (en) 2011-08-19
US20140031381A1 (en) 2014-01-30
SI2080514T1 (en) 2011-05-31
US20170319496A1 (en) 2017-11-09
SI2292229T1 (en) 2012-09-28
HK1165317A1 (en) 2013-12-06
BRPI0714539A2 (en) 2014-02-25
GT200900023A (en) 2010-11-05
PE20080765A1 (en) 2008-06-13
US20170348240A1 (en) 2017-12-07
EP2399579B9 (en) 2013-07-24
JP5373133B2 (en) 2013-12-18
US20170128373A1 (en) 2017-05-11
EP2070538A1 (en) 2009-06-17
ME01482B (en) 2014-04-20
US20150335584A1 (en) 2015-11-26
CN101583360A (en) 2009-11-18
CY1111887T1 (en) 2015-11-04
DE602007012747D1 (en) 2011-04-07
US20090081290A1 (en) 2009-03-26
DK2343071T3 (en) 2013-05-13
IL217791A (en) 2015-09-24
AR109797A2 (en) 2019-01-23
KR101496510B1 (en) 2015-03-03
RS52798B (en) 2013-10-31
US20170128440A1 (en) 2017-05-11
AU2007287341B2 (en) 2011-08-25
HRP20130433T1 (en) 2013-06-30
RS51678B (en) 2011-10-31
PL2070538T3 (en) 2011-05-31
US20170319489A1 (en) 2017-11-09
JP2012167102A (en) 2012-09-06
KR101455914B1 (en) 2014-11-03
JP6286491B2 (en) 2018-02-28
US20130251802A1 (en) 2013-09-26
KR20160099738A (en) 2016-08-22
CN102688241A (en) 2012-09-26
IL217791D0 (en) 2012-03-29
US10076499B2 (en) 2018-09-18
IL241121D0 (en) 2015-11-30
RS52402B (en) 2013-02-28
TWI341213B (en) 2011-05-01
ME01580B (en) 2014-09-20
SI2399580T1 (en) 2013-07-31
US20170319494A1 (en) 2017-11-09
MX2009002023A (en) 2009-03-05
PT2080514E (en) 2011-05-24
US20150335582A1 (en) 2015-11-26
MY161079A (en) 2017-04-14
NZ597760A (en) 2013-04-26
US8911719B2 (en) 2014-12-16
US20130251801A1 (en) 2013-09-26
CY1113141T1 (en) 2016-04-13
US20170128372A1 (en) 2017-05-11
PT2070538E (en) 2011-03-02
US20170319497A1 (en) 2017-11-09
US9775811B2 (en) 2017-10-03
EP2080514A1 (en) 2009-07-22
PT2082742E (en) 2011-03-02
RS52779B (en) 2013-10-31
EP2384754A1 (en) 2011-11-09
HK1156845A1 (en) 2012-10-26
EP2343071A1 (en) 2011-07-13
US20170319498A1 (en) 2017-11-09
PE20150340A1 (en) 2015-02-28
PL2399579T3 (en) 2013-12-31
IL217787D0 (en) 2012-03-29
US20170319492A1 (en) 2017-11-09
JO2858B1 (en) 2015-03-15
ES2411695T3 (en) 2013-07-08
EP2292230A1 (en) 2011-03-09
SI2292230T1 (en) 2012-09-28
US9486413B2 (en) 2016-11-08
EP2292229B1 (en) 2012-05-23
SI2070538T1 (en) 2011-03-31
UA104745C2 (en) 2014-03-11
US9770416B2 (en) 2017-09-26
KR101568100B1 (en) 2015-11-12
US20150037411A1 (en) 2015-02-05
CL2017000669A1 (en) 2017-11-10
HK1154491A1 (en) 2013-12-06
DOP2009000026A (en) 2009-07-15
US9095614B2 (en) 2015-08-04
IL197214D0 (en) 2009-12-24
KR20170118249A (en) 2017-10-24
EP2311459B1 (en) 2012-06-27
ES2417334T3 (en) 2013-08-07
EP2343071B1 (en) 2013-03-20
MY153092A (en) 2014-12-31
EA200900343A1 (en) 2009-08-28
KR101649838B1 (en) 2016-08-19
ES2388591T3 (en) 2012-10-16
HK1154788A1 (en) 2012-09-21
RS52813B (en) 2013-10-31
KR101205579B1 (en) 2012-11-28
US8834925B2 (en) 2014-09-16
PE20091184A1 (en) 2009-08-03
US20130251800A1 (en) 2013-09-26
CA2661573C (en) 2010-10-26
US20170128370A1 (en) 2017-05-11
EP2082742A1 (en) 2009-07-29
US9095615B2 (en) 2015-08-04
GT200900023BA (en) 2018-09-28
US20170319488A1 (en) 2017-11-09
HRP20130444T1 (en) 2013-06-30
EP2399580B1 (en) 2013-04-03
PT2384754E (en) 2013-05-24
US9486412B2 (en) 2016-11-08
JP2012236835A (en) 2012-12-06
AP200904770A0 (en) 2009-02-28
DE602007010963D1 (en) 2011-01-13
US20170128369A1 (en) 2017-05-11
CY1111897T1 (en) 2015-11-04
NZ608651A (en) 2014-07-25
AR062511A1 (en) 2008-11-12
CN102657630B (en) 2014-10-01
US8815289B2 (en) 2014-08-26
HRP20130434T1 (en) 2013-06-30
CN105213345B (en) 2019-04-19
US8821929B2 (en) 2014-09-02
US9492391B2 (en) 2016-11-15
DOP2011000255A (en) 2011-10-15
CN103861111A (en) 2014-06-18
CN105213345A (en) 2016-01-06
EP2399579A1 (en) 2011-12-28
ES2390419T3 (en) 2012-11-12
AU2007287341A1 (en) 2008-02-28
US20130251796A1 (en) 2013-09-26
CA2661573A1 (en) 2008-02-28
US20170319490A1 (en) 2017-11-09
US20170319495A1 (en) 2017-11-09
UA96306C2 (en) 2011-10-25
PL2384754T3 (en) 2013-12-31
JP5069300B2 (en) 2012-11-07
KR20110119847A (en) 2011-11-02
SI2399579T1 (en) 2013-07-31
US9492392B2 (en) 2016-11-15
ES2358066T3 (en) 2011-05-05
JP2012136543A (en) 2012-07-19
CA2707204C (en) 2015-06-23
PT2343071E (en) 2013-05-29
CN102688241B (en) 2017-04-12
US9545380B2 (en) 2017-01-17
HK1138498A1 (en) 2011-08-19
ME01187B (en) 2011-10-31
CL2007002485A1 (en) 2008-01-25
RS51664B (en) 2011-10-31
HRP20130539T1 (en) 2013-07-31
SI2384754T1 (en) 2013-07-31
PL2399580T3 (en) 2013-12-31
CY1111896T1 (en) 2015-11-04
HK1132189A1 (en) 2011-08-19
US9763933B2 (en) 2017-09-19
US20170319493A1 (en) 2017-11-09
US20170128371A1 (en) 2017-05-11
IL241122D0 (en) 2015-11-30
PT2292229E (en) 2012-08-28
EP2311459A1 (en) 2011-04-20
ME01550B (en) 2014-04-20
IL217789D0 (en) 2012-03-29
CN103861111B (en) 2017-04-12
HK1154789A1 (en) 2012-09-28
HRP20110147T1 (en) 2011-04-30
US20130260015A1 (en) 2013-10-03
US9775812B2 (en) 2017-10-03
ES2334466T3 (en) 2010-03-10
SA2709B1 (en) 2011-07-20
ME01339B (en) 2013-12-20
DK2070538T3 (en) 2011-03-21
ME01255B (en) 2013-06-20
PT2292230E (en) 2012-08-28
ES2411696T3 (en) 2013-07-08
CN107412179A (en) 2017-12-01
HK1118225A1 (en) 2010-02-26
PL2311459T3 (en) 2012-12-31
NZ574447A (en) 2012-04-27
EP2082742B1 (en) 2010-12-01
RS52401B (en) 2013-02-28
US20130259939A1 (en) 2013-10-03
US8894987B2 (en) 2014-11-25
IL241122A (en) 2019-05-30
DK2082742T3 (en) 2011-03-21
HRP20120641T1 (en) 2012-08-31
CN105267170A (en) 2016-01-27
US10076498B2 (en) 2018-09-18
US20170319491A1 (en) 2017-11-09
US20150265601A1 (en) 2015-09-24
CN105267170B (en) 2019-01-01
CY1110573T1 (en) 2015-04-29
CN102688213A (en) 2012-09-26
SI1897545T1 (en) 2010-01-29
KR20120105565A (en) 2012-09-25
SI2343071T1 (en) 2013-07-31
DK2080514T3 (en) 2011-05-16
US20170246116A1 (en) 2017-08-31
DK1897545T3 (en) 2010-02-08
US20150335585A1 (en) 2015-11-26
JP2015044834A (en) 2015-03-12
EP2080514B1 (en) 2011-02-23
JP2012229249A (en) 2012-11-22
JP2012229250A (en) 2012-11-22
PT1897545E (en) 2009-12-16
ES2417335T3 (en) 2013-08-07
IL217788D0 (en) 2012-03-29
JP5642736B2 (en) 2014-12-17
AT489953T (en) 2010-12-15
CN102743355B (en) 2014-12-24
DK2384754T3 (en) 2013-05-06
PT2399580E (en) 2013-07-05
US20170348241A1 (en) 2017-12-07
IL217794A (en) 2015-09-24
WO2008023261A1 (en) 2008-02-28
ES2357376T3 (en) 2011-04-25
TN2009000059A1 (en) 2010-08-19
US20150335583A1 (en) 2015-11-26
US9492393B2 (en) 2016-11-15
HRP20110130T1 (en) 2011-03-31
RS51591B (en) 2011-08-31
PL1897545T3 (en) 2010-02-26
EP2399580A1 (en) 2011-12-28
HK1165316A1 (en) 2013-12-06
DK2292229T3 (en) 2012-08-13
AT11571U1 (en) 2011-01-15
US9775808B2 (en) 2017-10-03
US20140030327A1 (en) 2014-01-30
CY1113220T1 (en) 2016-04-13
EP2292230B1 (en) 2012-05-23
DE202007011825U1 (en) 2008-04-30
TW200824722A (en) 2008-06-16
US20130251798A1 (en) 2013-09-26
HRP20120613T1 (en) 2012-08-31
PL2082742T3 (en) 2011-05-31
IN2015DN01813A (en) 2015-07-10
JP2016222698A (en) 2016-12-28
EA201171403A1 (en) 2012-05-30
DK2399579T3 (en) 2013-06-17
US20150265599A1 (en) 2015-09-24
US9775810B2 (en) 2017-10-03
EA023807B1 (en) 2016-07-29

Similar Documents

Publication Publication Date Title
TWI449540B (en) Process for the production of an abuse-proofed dosage form
IL196539D0 (en) Dosage form containing oxycodone and naloxone
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MY160456A (en) Benzodiazepine bromodomain inhibitor
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
HK1108152A1 (en) Apparatus for pharmaceutical production
EP1581188A4 (en) Pharmaceutical safety dosage forms
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
AP2303A (en) d-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
BRPI0717657A2 (en) Compounds, process for the preparation of a compound, pharmaceutical composition understanding, uses of compounds, methods for diabetes treatment and prophylaxy, obesity, dietary disorder and diphypethydia dypythesia
TW200612892A (en) Novel compounds
PL2046298T3 (en) Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
MX2012005810A (en) Amino oxazine derivatives.
WO2004093819A3 (en) Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
IL251539D0 (en) Unitary pharmaceutical dosage form
CY1116727T1 (en) Cure MULTIPLE HARDENING me laquinimod
EA200600320A1 (en) γ-CRYSTALLINE FORM OF Ivabradine Hydrochloride, its Method of Production and Pharmaceutical Compositions That It Contains
DK2080514T3 (en) Manipulation-safe oral pharmaceutical dosage forms comprising an opioid analgesic
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
CA2637672A1 (en) Sublingual fentanyl spray
EA200900023A1 (en) Use of substituted 2-aminothetralines for the production of medicines for the prevention, facilitation and / or treatment of different kinds of pain
NZ553751A (en) Cap for drug delivery devices

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years